within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09X_OtherAgentsActingOnTheReninAngiotensinSystem.C09XA01_Remikiren;

model Remikiren
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 1.5e-05,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.08,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006666666666666667,
    Tlag = 1800);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Remikiren</td></tr><tr><td>ATC code:</td><td>C09XA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>80</td><td>L</td></tr>
    <tr><td>clearance:</td><td>54</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Remikiren is a renin inhibitor, belonging to the class of antihypertensive agents. It was developed as an orally active, non-peptide inhibitor for the treatment of hypertension. However, it is not currently approved or marketed for medical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects following oral administration; no published clinical PK model identified.</p><h4>References</h4><ol><li><p>Weber, C, et al., &amp; Van Brummelen, P (1993). Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. <i>British journal of clinical pharmacology</i> 36(6) 547–554. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1993.tb00413.x\">10.1111/j.1365-2125.1993.tb00413.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12959271/\">https://pubmed.ncbi.nlm.nih.gov/12959271</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C09XA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Remikiren;
